Inventor · disambiguated record
Elena Geretti
Also filed as: GERETTI ELENA
3 granted patents·12 pending applications·2 citations·filing 2013–2019
55Inventor score
Top patents by PatentIndex Score
15 records- 0170US9226966B2Dosage and administration for preventing cardiotoxicity in treatment with ERBB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agentsMERRIMACK PHARMACEUTICALS INC·Filed 2013·Granted Jan 5, 2016·2 cites·10 claims
- 0266US2016067182A1Methods and compositions for improving outcomes of liposomal chemotherapyMERRIMACK PHARMACEUTICALS INC·Filed 2014·Application pending·0 cites
- 0359US2017231911A1Methods and compositions for improving outcomes of liposomal chemotherapyMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 0452US2015111217A1Marker quantitation in single cells in tissue sectionsMERRIMACK PHARMACEUTICALS INC·Filed 2013·Application pending·0 cites
- 0552US2016184227A1Methods and compositions for improving outcomes of liposomal chemotherapyMERRIMACK PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 0652US2017082630A1Marker quantitation in single cells in tissue sectionsMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 0750US9610249B2Dosage and administration for preventing cardiotoxicity in treatment with ERbB2-targeted immunoliposomes comprising anthracycline chemotherapeutic agentsMERRIMACK PHARMACEUTICALS INC·Filed 2015·Granted Apr 4, 2017·0 cites·22 claims
- 0850US2022008526A1Methods and compositions for cancer immunotherapyTORQUE THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 0949US2017189335A1Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracycline chemotherapeutic agentsMERRIMACK PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 1049US2017080087A1Combination Therapies for Treating Her2-Positive Cancers that are Resistant to Her2-Targeted TherapiesMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
- 1148US2016045596A1Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapiesMERRIMACK PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 1245US2016038416A1Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracycline chemotherapeutic agentsMERRIMACK PHARMACEUTICALS INC·Filed 2015·Application pending·0 cites
- 1343US9913901B2Combination therapy for treating HER2-positive cancersMERRIMACK PHARMACEUTICALS INC·Filed 2013·Granted Mar 13, 2018·0 cites·22 claims
- 1439US2017258903A1Combination therapies for treating her2-positive cancers that are resistant to her2-targeted therapiesMERRIMACK PHARMACEUTICALS INC·Filed 2017·Application pending·0 cites
- 1537US2017022290A1Combination therapies for treating her2-positive cancersMERRIMACK PHARMACEUTICALS INC·Filed 2016·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Elena Geretti files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →